Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,206,763 papers from all fields of science
Search
Sign In
Create Free Account
3,4-dihydroxybenzohydroxamic acid
Known as:
Benzamide, N,3,4-trihydroxy-
, Didox
, N,3,4-trihydroxybenzamide
A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (3)
Antineoplastic Agents
Enzyme Inhibitors
Hydroxamic Acids
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact
K. C. Clark
,
A. Josephson
,
+12 authors
J. Dupree
Glia
2016
Corpus ID: 3689312
Axonal pathology is a key contributor to long‐term disability in multiple sclerosis (MS), an inflammatory demyelinating disease…
Expand
2016
2016
Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity
Sahar A. Khaleel
,
A. M. Al-Abd
,
A. Ali
,
A. Abdel-Naim
Scientific reports
2016
Corpus ID: 12427249
Doxorubicin (DOX) has limited efficacy in colorectal cancer due to multi-drug resistance. Resveratrol (RES) and didox (DID) are…
Expand
2015
2015
Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
K. Shah
,
E. Wilson
,
Ritu Malla
,
H. Elford
,
Jesika S. Faridi
Molecular Cancer Therapeutics
2015
Corpus ID: 6237469
Tamoxifen is widely used as an adjuvant therapy for patients with estrogen receptor (ERα)–positive tumors. However, the clinical…
Expand
2013
2013
AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
K. Shah
,
Kshama Mehta
,
David A. Peterson
,
Marie Evangelista
,
J. Livesey
,
Jesika S. Faridi
Molecular Cancer Research
2013
Corpus ID: 10930338
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves…
Expand
2013
2013
Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity.
A. M. Al-Abd
,
F. Al-Abbasi
,
Gihan F. Asaad
,
A. Abdel-Naim
European journal of pharmacology
2013
Corpus ID: 5225863
2004
2004
Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase
T. Szekeres
,
K. Gharehbaghi
,
+5 authors
H. Elford
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 29029753
Trimidox (3,4,5-trihydroxybenzamidoxime), a newly synthesized analog of didox (N,3,4-trihydroxybenzamide) reduced the activity of…
Expand
Highly Cited
2003
Highly Cited
2003
Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants
J. Turchan
,
C. Pocernich
,
+10 authors
A. Nath
Neurology
2003
Corpus ID: 7527900
Objective: To determine the role of oxidative stress in mediating HIV dementia and to identify novel therapeutic compounds that…
Expand
Highly Cited
2003
Highly Cited
2003
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
E. Månsson
,
Emma Flordal
,
+5 authors
F. Albertioni
Biochemical pharmacology
2003
Corpus ID: 23807643
1988
1988
A phase 1 and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor.
D. Veale
,
J. Carmichael
,
+5 authors
A. Harris
British Journal of Cancer
1988
Corpus ID: 6642109
A phase 1 study of a new ribonucleotide reductase inhibitor, didox, was performed by administration of escalating doses of the…
Expand
Highly Cited
1980
Highly Cited
1980
Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents.
H. Elford
,
B. van't Riet
,
G. Wampler
,
A. L. Lin
,
R. Elford
Advances in enzyme regulation
1980
Corpus ID: 22126992
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE